Is it worth buying McKesson stock at a price of $454.52? If this question is on your mind, make sure to check out the fundamentals of this Pharmaceutical large-cap company:
-
McKesson has logged a 23.0% 52 week change, compared to 14.0% for the S&P 500
-
MCK has an average analyst rating of buy and is -6.54% away from its mean target price of $486.33 per share
-
Its trailing earnings per share (EPS) is $26.83, which brings its trailing Price to Earnings (P/E) ratio to 16.9. The Health Care sector's average P/E ratio is 24.45
-
The company's forward earnings per share (EPS) is $30.68 and its forward P/E ratio is 14.8
-
The current ratio is currently 1.0, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
MCK has reported YOY quarterly earnings growth of 33.4% and gross profit margins of 0.0%
-
The company's free cash flow for the last fiscal year was $4.82 Billion and the average free cash flow growth rate is 0.0%
-
McKesson's revenues have an average growth rate of 0.0% with operating expenses growing at -15.1%. The company's current operating margins stand at 1.0%